• About
  • Licensing
  • Podcasting
  • Contact

AudioMedica.com

  • Public Health
  • Oncology
  • Cardiovascular
  • General Medicine

Integrase Inhibitor Raltegravir Doubles Antiviral Response Rate in Treatment Experienced HIV-Infected Patients Compared to Optimised Background Therapy Alone

  • in Public Health
  • — 6 Mar, 2007
Integrase Inhibitor Raltegravir Doubles Antiviral Response Rate in Treatment Experienced HIV-Infected Patients Compared to Optimised Background Therapy Alone
AudioMedica News
Integrase Inhibitor Raltegravir Doubles Antiviral Response Rate in Treatment Experienced HIV-Infected Patients Compared to Optimised Background Therapy Alone
Integrase Inhibitor Raltegravir Doubles Antiviral Response Rate in Treatment Experienced HIV-Infected Patients Compared to Optimised Background Therapy Alone
00:00 /
RSS Feed
Share
Link
Embed
//-->//>' class="input-embed input-embed-243"/>
Roy Steigbigel

John Mellors

ROY STEIGBIGEL, State University of New York at Stony Brook
JOHN W. MELLORS, University of Pittsburgh

REFERENCE: Abstract 105aLB, 105bLB, 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles February 25-28, 2007
Raltegravir doubled the antiviral response rate and the increase in CD4 cells among treatment-experienced HIV-infected patients who were resistant to at least one drug in each of the nucleoside, non-nucleoside, and protease inhibitor classes. Two placebo controlled trials (BENCHMRK-1 and BENCHMRK-2) randomized a total of almost 700 subjects to either raltegravir 400 mg twice daily or to placebo, each on a background of optimized antiviral background therapy. Raltegravir is an integrase inhibitor and acts to block the enzyme that allows HIV’s nuclei acid to integrate into the DNA of host cells. At the Los Angeles conference Dan Keller heard about the studies from Roy Steigbigel and John Mellors.

[audio:https://www.audiomedica.com/podcasting/global_health/070307_steigbigel_mellors_podcast.mp3]

You may also like...

  • Cathy Zimmerman Migrant Health: A Key Issue For Global Health 29 May, 2011
  • Obesity, Car Travel, Climate Change: Linked? Obesity, Car Travel, Climate Change: Linked? 11 Jun, 2008
  • The Health Benefits Of Tackling Climate Change The Health Benefits Of Tackling Climate Change 5 Dec, 2009
  • Krishnan Bhaskaran Cooler Weather – More Heart Attacks 18 Oct, 2010

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

  • Previous story Entecavir Shows Activity Against HIV But Also Selects for an Antiretroviral Drug Resistance Mutation
  • Next story Maraviroc: New Antiretroviral Drug Shows Efficacy and Safety
  • News

    • Mandeep Mehra MDCOVID-19 Co-Morbidity Risks Quantified from Three Continents SurveyMay 28, 2020
    • Ultrahypofractionated Radiation Just As Effective for Prostate CancerUltrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014
  • Related interviews

    • Microbiome Diversity Key To Survival After…
    • Ibrutinib: New Frontline Standard for Chronic…
    • New Front Line Standard for Older Patients with…
    • Which Tasks Most Influence Pediatric PT…
    • Childhood Obesity—Whose Business Is It?
  • Home
  • Public Health
  • Integrase Inhibitor Raltegravir Doubles Antiviral Response Rate in Treatment Experienced HIV-Infected Patients Compared to Optimised Background Therapy Alone

© COPYRIGHT 2020 AUDIOMEDICA.COM.